Table 1 Characteristics of baseline BZD users and non-users
|  | Initially negative (n = 3288, 85.4%) | Initially positive (n = 562, 14.6%) | |
|---|---|---|---|
Male/female | 1975 (60.1%)/1313 (39.9%) | 316 (56.2%)/246 (43.8%) | |
North/South | 1239 (37.7%)/2048 (62.3%) | 166 (29.5%)/396 (70.5%) | |
Urban/rural | 2753 (83.8%)/543 (16.2%) | 499 (88.8%)/63 (11.2%) | |
Median age (Q 1, Q 3; SD) | 30.8 (25.3, 39.4; SD = 10.2) | 34.3 (28.1, 45.3; SD = 10.9) | |
Median peak methadone dose (Q 1, Q 3; SD) | 75 (50, 100; SD = 33) | 85 (55, 115; SD = 36) | |
Median peak suboxone dose ( Q 1, Q 3; SD) | 8 (8, 16; SD = 7) | 12 (8, 20; SD = 8) | |
Median days retained (Q 1, Q 3; SD) | 265 (56, 526; SD = 272) | 215 (53, 519; SD = 270) | |
Median percent positive results (Q 1, Q 3; SD) | 0.0 (0.0, 0.0; SD = 4.9) | 21.4 (6.8, 55.1; SD = 32.1) | |
Percent positive results | [0, 25) | 3252 (98.9%) | 302 (53.7%) |
[25, 50) | 31 (0.9%) | 96 (17.1%) | |
[50, 75) | 4 (0.1%) | 68 (12.1%) | |
[75, 100] | 1 (<0.1%) | 96 (17.1%) | |
At month 3 Day 60 to 90 | Positive/negative | 144 (6.0%)/2276 (94.0%) | 204 (50.5%)/200 (49.5%) |
Retained | 2420 (73.6%) | 404 (71.9%) | |
At Month 6 Day 150 to 180 | Positive/negative | 109 (5.6%)/1850 (94.4%) | 128 (40.9%)/185 (59.1%) |
Retained | 1959 (59.6%) | 313 (55.7%) | |
At Month 9 Day 240 to 270 | Positive/negative | 88 (5.2%)/1601 (94.8%) | 104 (39.0%)/163 (61.0%) |
Retained | 1689 (51.4%) | 267 (47.5%) | |
At Month 12 Day 330 to 360 | Positive/negative | 80 (5.3%)/1443 (94.7%) | 74 (31.2%)/163 (68.8%) |
Retained | 1523 (46.3%) | 237 (42.2%) | |
Retained/not retained 365 Days | 1447 (44.0%)/1841 (56.0%) | 224 (39.9%)/338 (60.1%) | |